SYNB:NYE-Putnam Biorevolution ETF (USD)

ETF | Others |

Last Closing

USD 30.9453

Change

+0.19 (+0.63)%

Market Cap

USD 5.29M

Volume

100.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
SOJE SOJE

-0.02 (-0.10%)

USD 65.72B
JEPI JPMorgan Equity Premium Income..

+0.17 (+0.30%)

USD 32.43B
DTB DTB

+0.15 (+0.75%)

USD 26.58B
DFAC Dimensional U.S. Core Equity 2..

+0.23 (+0.75%)

USD 26.00B
GBTC Grayscale Bitcoin Trust (BTC)

-0.86 (-1.49%)

USD 23.75B
JPST JPMorgan Ultra-Short Income ET..

+0.01 (+0.02%)

USD 22.73B
SGOV iShares® 0-3 Month Treasury B..

+0.02 (+0.02%)

USD 19.79B
AVUV Avantis® U.S. Small Cap Value..

+0.35 (+0.39%)

USD 10.49B
DFUV Dimensional US Marketwide Valu..

+0.01 (+0.03%)

USD 10.15B
DFAT Dimensional U.S. Targeted Valu..

+0.34 (+0.66%)

USD 9.40B

ETFs Containing SYNB

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.34% 64% D 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.34% 62% D 61% D-
Trailing 12 Months  
Capital Gain 15.44% 59% D- 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.44% 54% F 55% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 1.93% 65% D 50% F
Dividend Return 1.93% 58% F 39% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 4.67% 80% B- 94% A
Risk Adjusted Return 41.35% 68% D+ 68% D+
Market Capitalization 5.29M 14% F 4% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.